Table 2 Effect of baseline characteristics on treatment response represented as the percentage of mITT subjects in each subgroup achieving sUA <6.0 mg/dL at Final Visit

Renal Function ^a

   Moderately Impaired

43.1 (56/130)

71.3 (97/136)

31.6 (43/136)

   Mildly Impaired

52.1 (182/349)

71.7 (263/367)

46.3 (169/365)

   Normal

37.4 (104/278)

58.1 (147/253)

41.7 (106/254)

Baseline Serum Urate (mg/dL) ^a

   <9.0

60.1 (170/283)

80.4 (225/280)

52.7 (144/273)

   9.0 to <10.0

47.1 (106/225)

70.7 (157/222)

40.5 (102/252)

   ≥10.0

26.5 (66/249)

49.2 (125/254)

31.3 (72/230)

Baseline Tophus ^a

   No

48.1 (284/591)

69.8 (414/593)

44.6 (271/607)

   Yes

34.9 (58/166)

57.1 (93/163)

31.8 (47/148)

Completed Prior Febuxostat Study ^a

   No

43.4 (286/659)

65.7 (439/668)

40.8 (271/665)

   Yes

57.1 (56/98)

77.3 (68/88)

52.2 (47/90)